Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Amylyx Pharmaceuticals Inc. | AMX0035 - (HELIOS) | Wolfram Syndrome | Phase 2 | Data Released | Oral | Genetic Disorder |
| Amylyx Pharmaceuticals Inc. | AMX0035 - (A35-004 PHOENIX) | Amyotrophic Lateral Sclerosis (AML) | Phase 3 | Trial Discontinued | Oral | Neurology |
| Amylyx Pharmaceuticals Inc. | RELYVRIO (sodium phenylbutyrate and taurursodiol) | Amyotrophic lateral sclerosis (ALS) | Phase 3 | Withdrawn | oral | Neurology |
| Amylyx Pharmaceuticals Inc. | AMX0035 - (PEGASUS) | Alzheimer's Disease | Phase 2 | Data Released | oral | Neurology |
| AN2 Therapeutics Inc. | EBO-301 | Treatment-Refractory MAC Lung Disease | Phase 3 | Trial Completed | Intravenous | Respiratory |
| AN2 Therapeutics Inc. | Epetraborole | Melioidosis | Phase 2 | Trial Planned | Oral | Antibiotic |
| AN2 Therapeutics Inc. | Epetraborole - (EBO-103) | Mycobacterium avium complex (MAC) lung disease, Chronic non-tuberculous mycobacterial (NTM) lung disease | Phase 2/3 | Data Released | Oral | Respiratory |
| AnaptysBio Inc. | Jemperli (dostarlimab) plus chemotherapy - (PERLA) | Non-squamous non-small cell lung cancer (NSCLC) | Phase 2 | Trial Completed | Intravenous | Oncology |
